EP3561058A4 - FUSION PROTEIN INCLUDING BDNF - Google Patents
FUSION PROTEIN INCLUDING BDNF Download PDFInfo
- Publication number
- EP3561058A4 EP3561058A4 EP17885951.8A EP17885951A EP3561058A4 EP 3561058 A4 EP3561058 A4 EP 3561058A4 EP 17885951 A EP17885951 A EP 17885951A EP 3561058 A4 EP3561058 A4 EP 3561058A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- fusion protein
- protein including
- including bdnf
- bdnf
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150035467 BDNF gene Proteins 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Environmental Sciences (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016252147 | 2016-12-26 | ||
PCT/JP2017/046735 WO2018124107A1 (ja) | 2016-12-26 | 2017-12-26 | Bdnfを含む融合蛋白質 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3561058A1 EP3561058A1 (en) | 2019-10-30 |
EP3561058A4 true EP3561058A4 (en) | 2020-07-22 |
Family
ID=62709408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17885951.8A Pending EP3561058A4 (en) | 2016-12-26 | 2017-12-26 | FUSION PROTEIN INCLUDING BDNF |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200384061A1 (zh) |
EP (1) | EP3561058A4 (zh) |
JP (3) | JP7072524B2 (zh) |
KR (1) | KR102573622B1 (zh) |
CN (1) | CN110100000B (zh) |
AU (1) | AU2017385274B2 (zh) |
CA (1) | CA3052936A1 (zh) |
TW (1) | TWI791006B (zh) |
WO (1) | WO2018124107A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11130815B2 (en) | 2015-06-24 | 2021-09-28 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
EA201991577A1 (ru) * | 2016-12-26 | 2019-12-30 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер |
US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
US10143187B2 (en) * | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
WO2018152326A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
JP7102790B2 (ja) * | 2018-03-07 | 2022-07-20 | 富士通株式会社 | データ生成方法、データ生成プログラム及び情報処理装置 |
AU2022235471A1 (en) | 2021-03-10 | 2023-09-21 | Sumitomo Pharma Co., Ltd. | Method for producing fusion protein |
WO2022239817A1 (ja) * | 2021-05-12 | 2022-11-17 | Jcrファーマ株式会社 | ムコ多糖症i型の治療用医薬組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995002421A1 (en) * | 1993-07-16 | 1995-01-26 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
WO2016208696A1 (ja) * | 2015-06-24 | 2016-12-29 | Jcrファーマ株式会社 | Bdnfを含む融合蛋白質 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229500A (en) | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
US5154924A (en) | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
JPH06228199A (ja) | 1992-11-27 | 1994-08-16 | Takeda Chem Ind Ltd | 血液脳関門通過可能なペプチド結合体 |
US6261558B1 (en) | 1993-10-19 | 2001-07-17 | The Scripps Research Institute | Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus |
EP0817794A1 (en) | 1995-03-31 | 1998-01-14 | Jakob Bohr | Method for protein folding |
AUPN523995A0 (en) | 1995-09-05 | 1995-09-28 | Crc For Biopharmaceutical Research Pty Ltd | Method for producing phage display vectors |
CN1713920A (zh) * | 2002-08-30 | 2005-12-28 | 比奥雷克西斯药物公司 | 被修饰的转铁蛋白融合蛋白 |
US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
CN101495141B (zh) * | 2005-12-13 | 2015-10-07 | 阿斯利康(瑞典)有限公司 | 胰岛素样生长因子特异性结合蛋白及其用途 |
AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
US20100077498A1 (en) * | 2008-09-11 | 2010-03-25 | Pardridge William M | Compositions and methods for blood-brain barrier delivery in the mouse |
JP2012034668A (ja) * | 2010-08-12 | 2012-02-23 | Tohoku Univ | ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用 |
JP2012062312A (ja) | 2010-08-19 | 2012-03-29 | Yoshikatsu Eto | ハンター症候群の治療剤 |
WO2012063799A1 (ja) | 2010-11-08 | 2012-05-18 | 日本ケミカルリサーチ株式会社 | 新規発現ベクター |
TWI689314B (zh) | 2010-11-30 | 2020-04-01 | 建南德克公司 | 低親和力血腦障壁受體抗體及其用途 |
CA2828662A1 (en) | 2011-04-20 | 2012-10-26 | Roche Glycart Ag | Method and constructs for the ph dependent passage of the blood-brain-barrier |
US20150353639A1 (en) | 2012-05-21 | 2015-12-10 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
EP3088518A4 (en) * | 2013-12-25 | 2017-09-20 | JCR Pharmaceuticals Co., Ltd. | Novel anti-transferrin receptor antibody that passes through blood-brain barrier |
-
2017
- 2017-12-26 AU AU2017385274A patent/AU2017385274B2/en active Active
- 2017-12-26 KR KR1020197021119A patent/KR102573622B1/ko active IP Right Grant
- 2017-12-26 CA CA3052936A patent/CA3052936A1/en active Pending
- 2017-12-26 US US16/473,816 patent/US20200384061A1/en active Pending
- 2017-12-26 JP JP2018559532A patent/JP7072524B2/ja active Active
- 2017-12-26 EP EP17885951.8A patent/EP3561058A4/en active Pending
- 2017-12-26 CN CN201780080518.2A patent/CN110100000B/zh active Active
- 2017-12-26 WO PCT/JP2017/046735 patent/WO2018124107A1/ja unknown
- 2017-12-26 TW TW106145826A patent/TWI791006B/zh active
-
2022
- 2022-05-10 JP JP2022077514A patent/JP7427046B2/ja active Active
-
2023
- 2023-11-02 JP JP2023188680A patent/JP2024001350A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995002421A1 (en) * | 1993-07-16 | 1995-01-26 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
WO2016208696A1 (ja) * | 2015-06-24 | 2016-12-29 | Jcrファーマ株式会社 | Bdnfを含む融合蛋白質 |
Non-Patent Citations (4)
Title |
---|
CHAO M V ET AL: "Neurotrophins and their receptors: A convergence point for many signalling pathways", NATURE REVIEWS NEUROSCIENCE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 4, 1 January 2003 (2003-01-01), pages 299 - 309, XP003020518, ISSN: 1471-0048, DOI: 10.1038/NRN1078 * |
PARDRIDGE W M ET AL: "Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier", THE RESOLUTION REVOLUTION: RECENT ADVANCES IN CRYOEM; [METHODS IN ENZYMOLOGY], ELSEVIER, vol. 503, 1 January 2012 (2012-01-01), pages 269 - 292, XP009156984, ISSN: 0076-6879, ISBN: 978-0-12-805382-9, [retrieved on 20120108], DOI: 10.1016/B978-0-12-396962-0.00011-2 * |
PARDRIDGE WILLIAM M: "Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody", EXPERT OPINION ON DRUG DELIVERY, INFORMA HEALTHCARE, UK, vol. 12, no. 2, 1 February 2015 (2015-02-01), pages 207 - 222, XP009183494, ISSN: 1744-7593, DOI: 10.1517/17425247.2014.952627 * |
RINAT TABAKMAN ET AL: "Interactions between the cells of the immune and nervous system: neurotrophins as neuroprotection mediators in CNS injury", NGF AND RELATED MOLECULES IN HEALTH AND DISEASE : [7TH INTERNATIONAL CONFERENCE ON NGF AND RELATED MOLECULES HELD IN MODENA, ITALY FROM 15 TO 19 MAY, 2002]; IN: PROGRESS IN BRAIN RESEARCH , ISSN 0079-6123 ; VOL. 146, vol. 146, 1 January 2004 (2004-01-01) - 19 May 2002 (2002-05-19), NL, pages 385 - 401, XP055525844, ISBN: 978-0-444-51472-1, DOI: 10.1016/S0079-6123(03)46024-X * |
Also Published As
Publication number | Publication date |
---|---|
AU2017385274A1 (en) | 2019-08-08 |
AU2017385274B2 (en) | 2024-02-22 |
WO2018124107A1 (ja) | 2018-07-05 |
TW201829471A (zh) | 2018-08-16 |
KR102573622B1 (ko) | 2023-08-31 |
JP2022110056A (ja) | 2022-07-28 |
CA3052936A1 (en) | 2018-07-05 |
TWI791006B (zh) | 2023-02-01 |
CN110100000A (zh) | 2019-08-06 |
JPWO2018124107A1 (ja) | 2019-10-31 |
KR20190097217A (ko) | 2019-08-20 |
JP7072524B2 (ja) | 2022-05-20 |
CN110100000B (zh) | 2023-06-20 |
JP2024001350A (ja) | 2024-01-09 |
US20200384061A1 (en) | 2020-12-10 |
JP7427046B2 (ja) | 2024-02-02 |
EP3561058A1 (en) | 2019-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3519442A4 (en) | IMMUNOMODULATORY FUSION PROTEINS | |
EP3402823A4 (en) | MULTIVALENT AND MULTISPECIFIC 41BB BINDING FUSION PROTEINS | |
EP3430058A4 (en) | MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF | |
EP3402507A4 (en) | MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS | |
EP3325512A4 (en) | MULTIVALENT AND MULTISPECIFIC HYBRID PROTEINS BINDING TO GITR | |
EP3287470A4 (en) | Novel recombinant bi-functional fusion protein and preparation and application therefor | |
EP3197453B8 (en) | Chimeric protein | |
EP3188758A4 (en) | Sirp alpha-antibody fusion proteins | |
GB201509413D0 (en) | Fusion protein | |
EP3280727A4 (en) | TYPE I AND SINGLE-ARM TYPE II RECEPTOR FUSION PROTEINS AND USES THEREOF | |
EP3122371A4 (en) | Fgf23 fusion proteins | |
EP3561058A4 (en) | FUSION PROTEIN INCLUDING BDNF | |
EP3880814A4 (en) | FUSION PROTEIN | |
EP3578570A4 (en) | MULTIFUNCTIONAL PROTEIN | |
EP3274457A4 (en) | Follistatin-related fusion proteins and uses thereof | |
EP3315515A4 (en) | HYBRID PROTEIN CONTAINING A BDNF | |
EP3199555A4 (en) | Recombinant fusion protein formulation | |
EP3199179A4 (en) | Recombinant fusion protein formulation | |
EP3757218A4 (en) | MERGER PROTEIN | |
EP3562299A4 (en) | INSECTICIDE PROTEINS | |
EP3344278A4 (en) | INSULIN-IMMUNOGLOBULIN FUSION PROTEINS | |
EP3322734A4 (en) | MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS | |
EP3531824A4 (en) | INSECTICIDE PROTEINS | |
EP3463414A4 (en) | PROTEIN INTERFACES | |
EP3722305A4 (en) | HM-3 FUSION PROTEIN AND USES THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190724 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40008823 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200619 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/10 20060101ALI20200615BHEP Ipc: A61P 25/24 20060101ALI20200615BHEP Ipc: C07K 19/00 20060101ALI20200615BHEP Ipc: C12N 15/09 20060101AFI20200615BHEP Ipc: A61P 25/04 20060101ALI20200615BHEP Ipc: A61P 25/08 20060101ALI20200615BHEP Ipc: A61P 25/22 20060101ALI20200615BHEP Ipc: A61P 25/02 20060101ALI20200615BHEP Ipc: A61P 25/28 20060101ALI20200615BHEP Ipc: A61P 27/02 20060101ALI20200615BHEP Ipc: A61P 25/18 20060101ALI20200615BHEP Ipc: A61P 25/14 20060101ALI20200615BHEP Ipc: A61P 25/00 20060101ALI20200615BHEP Ipc: A61P 25/16 20060101ALI20200615BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20221202 |